Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRojano-Toimil, Alba
dc.contributor.authorRivera Esteban, Jesus Manuel
dc.contributor.authorManzano Nuñez, Ramiro
dc.contributor.authorJuan Bañares Sanchez, Juan
dc.contributor.authorMartinez Selva, David
dc.contributor.authorGabriel Medina, Pablo
dc.contributor.authorFerrer Costa, Roser
dc.contributor.authorPericàs Pulido, Juan Manuel
dc.contributor.authorCiudin Mihai, Andreea
dc.date.accessioned2022-09-12T09:30:12Z
dc.date.available2022-09-12T09:30:12Z
dc.date.issued2022-06-08
dc.identifier.citationRojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, et al. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med. 2022 Jun 8;11(12):3286.
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/11351/8148
dc.descriptionMODY diabetes; Liver fibrosis; Type 2 diabetes
dc.description.abstractType 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly common in other types of diabetes such as type 1 diabetes (T1DM) and less frequently ketone-prone and Maturity-onset Diabetes of the Young (MODY) diabetes. In this review, we address the relationship between hyperglycemia and insulin resistance and the onset and progression of NAFLD. In addition, despite the high rate of patients with T2DM and other diabetes phenotypes that can alter liver metabolism and consequently develop steatosis, fibrosis, and cirrhosis, NALFD screening is not still implemented in the daily care routine. Incorporating a clinical algorithm created around a simple, non-invasive, cost-effective model would identify high-risk patients. The principle behind managing these patients is to improve insulin resistance and hyperglycemia states with lifestyle changes, weight loss, and new drug therapies.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;11(12)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFenotip
dc.subjectDiabetis no-insulinodependent
dc.subjectEsteatosi hepàtica - Diagnòstic
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.mesh/diagnosis
dc.subject.meshPhenotype
dc.titleWhen Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm11123286
dc.subject.decsdiabetes mellitus tipo II
dc.subject.decsesteatosis hepática no alcohólica
dc.subject.decs/diagnóstico
dc.subject.decsfenotipo
dc.relation.publishversionhttps://doi.org/10.3390/jcm11123286
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rojano-Toimil A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rivera-Esteban J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Manzano-Nuñez R, Bañares J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martinez Selva D] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain. [Gabriel-Medina P] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pericàs JM] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Hepàtica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Network of Biomedical Research Centers, Liver and Digestive Diseases (CIBERehd), Madrid, Spain. [Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Network of Biomedical Research Centers, Diabetes and Metabolic Associated Disorders (CIBERdem), Madrid, Spain
dc.identifier.pmid35743358
dc.identifier.wos000817683200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record